CL2016000543A1 - Uso de pidotimod o sus estereoisómeros y/o sales fisiológicamente aceptables para preparar un medicamento útil en el tratamiento de enfermedades asociadas con la inflamación, donde hay una hiperactivación aberrante de la vía no canónica de nfkb. - Google Patents
Uso de pidotimod o sus estereoisómeros y/o sales fisiológicamente aceptables para preparar un medicamento útil en el tratamiento de enfermedades asociadas con la inflamación, donde hay una hiperactivación aberrante de la vía no canónica de nfkb.Info
- Publication number
- CL2016000543A1 CL2016000543A1 CL2016000543A CL2016000543A CL2016000543A1 CL 2016000543 A1 CL2016000543 A1 CL 2016000543A1 CL 2016000543 A CL2016000543 A CL 2016000543A CL 2016000543 A CL2016000543 A CL 2016000543A CL 2016000543 A1 CL2016000543 A1 CL 2016000543A1
- Authority
- CL
- Chile
- Prior art keywords
- pidotimod
- inflammation
- prepare
- treatment
- physiologically acceptable
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0046—Ear
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Ophthalmology & Optometry (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Otolaryngology (AREA)
- Heart & Thoracic Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Child & Adolescent Psychology (AREA)
- Obesity (AREA)
- Psychology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
Abstract
USO DE PIDOTIMOD O SUS ESTEREOISÓMEROS Y/O SALES FISIOLÓGICAMENTE ACEPTABLES PARA PREPARAR UN MEDICAMENTO ÚTIL EN EL TRATAMIENTO DE ENFERMEDADES ASOCIADAS CON LA INFLAMACIÓN, DONDE HAY UNA HIPERACTIVACIÓN ABERRANTE DE LA VÍA NO CANÓNICA DE NFkB.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/EP2013/068701 WO2015036009A1 (en) | 2013-09-10 | 2013-09-10 | Pidotimod for use in the treatment of inflammation-associated diseases |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2016000543A1 true CL2016000543A1 (es) | 2016-11-04 |
Family
ID=49118554
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2016000543A CL2016000543A1 (es) | 2013-09-10 | 2016-03-09 | Uso de pidotimod o sus estereoisómeros y/o sales fisiológicamente aceptables para preparar un medicamento útil en el tratamiento de enfermedades asociadas con la inflamación, donde hay una hiperactivación aberrante de la vía no canónica de nfkb. |
Country Status (18)
Country | Link |
---|---|
US (1) | US20160213651A1 (es) |
EP (2) | EP3043796A1 (es) |
JP (1) | JP2016529327A (es) |
KR (1) | KR20160052582A (es) |
CN (1) | CN105555267A (es) |
AU (1) | AU2014320474A1 (es) |
CA (1) | CA2922739A1 (es) |
CL (1) | CL2016000543A1 (es) |
EA (1) | EA201690574A1 (es) |
HK (1) | HK1223041A1 (es) |
IL (1) | IL244435A0 (es) |
MD (1) | MD20160040A2 (es) |
MX (1) | MX2016003195A (es) |
PE (1) | PE20160649A1 (es) |
PH (1) | PH12016500472A1 (es) |
SG (1) | SG11201601203TA (es) |
TW (1) | TW201542206A (es) |
WO (2) | WO2015036009A1 (es) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108003221B (zh) * | 2017-12-14 | 2020-08-11 | 北京金城泰尔制药有限公司 | 匹多莫德缩合杂质的去除工艺 |
KR102068289B1 (ko) | 2018-06-20 | 2020-01-20 | 남희정 | 렌즈 교환형 안경 |
CN113577242B (zh) * | 2021-04-20 | 2023-12-08 | 中山大学附属第五医院 | Nlrp12在制备治疗冠状病毒感染或相关的炎症性疾病的药物中的应用 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT1230706B (it) * | 1989-02-10 | 1991-10-29 | Poli Ind Chimica Spa | Derivati dell'acido 3 piroglutamoil tiazolidin 4 carbossilico e loro proprieta' farmacologiche. |
IT1231723B (it) | 1989-08-11 | 1991-12-21 | Poli Ind Chimica Spa | Derivati dell'acido piroglutammico, loro preparazioni e composizioni farmaceutiche che li contengono |
IT1240353B (it) * | 1990-03-30 | 1993-12-07 | Poli Ind Chimica Spa | Formulazioni liposomiali di farmaci immunomodulatori per applicazionelocale ed aerosolica |
CN1225245C (zh) * | 2004-01-16 | 2005-11-02 | 太阳石(唐山)药业有限公司 | 匹多莫德在制备治疗乙肝药物中的应用 |
AU2012396942A1 (en) * | 2012-12-19 | 2015-07-02 | Polichem S.A. | Use of pidotimod to treat psoriasis |
MX2015008129A (es) * | 2012-12-19 | 2015-09-23 | Polichem Sa | Uso de pidotimod para tratar la dermatitis atopica. |
KR20150012167A (ko) * | 2013-07-24 | 2015-02-03 | 주식회사 포벨 | 초고속 통신용 광 모듈 |
-
2013
- 2013-09-10 WO PCT/EP2013/068701 patent/WO2015036009A1/en active Application Filing
-
2014
- 2014-09-03 TW TW103130366A patent/TW201542206A/zh unknown
- 2014-09-08 EA EA201690574A patent/EA201690574A1/ru unknown
- 2014-09-08 MX MX2016003195A patent/MX2016003195A/es unknown
- 2014-09-08 EP EP14761638.7A patent/EP3043796A1/en not_active Withdrawn
- 2014-09-08 US US14/917,301 patent/US20160213651A1/en not_active Abandoned
- 2014-09-08 MD MDA20160040A patent/MD20160040A2/ro not_active Application Discontinuation
- 2014-09-08 WO PCT/EP2014/069103 patent/WO2015036370A1/en active Application Filing
- 2014-09-08 JP JP2016541907A patent/JP2016529327A/ja active Pending
- 2014-09-08 KR KR1020167007206A patent/KR20160052582A/ko not_active Application Discontinuation
- 2014-09-08 CN CN201480049183.4A patent/CN105555267A/zh active Pending
- 2014-09-08 PE PE2016000351A patent/PE20160649A1/es not_active Application Discontinuation
- 2014-09-08 CA CA2922739A patent/CA2922739A1/en not_active Abandoned
- 2014-09-08 AU AU2014320474A patent/AU2014320474A1/en not_active Abandoned
- 2014-09-08 SG SG11201601203TA patent/SG11201601203TA/en unknown
- 2014-09-08 EP EP16197220.3A patent/EP3146966A1/en not_active Withdrawn
-
2016
- 2016-03-03 IL IL244435A patent/IL244435A0/en unknown
- 2016-03-09 CL CL2016000543A patent/CL2016000543A1/es unknown
- 2016-03-10 PH PH12016500472A patent/PH12016500472A1/en unknown
- 2016-09-29 HK HK16111420.9A patent/HK1223041A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
MD20160040A2 (ro) | 2016-07-31 |
WO2015036009A1 (en) | 2015-03-19 |
MX2016003195A (es) | 2016-11-14 |
EP3043796A1 (en) | 2016-07-20 |
TW201542206A (zh) | 2015-11-16 |
HK1223041A1 (zh) | 2017-07-21 |
US20160213651A1 (en) | 2016-07-28 |
SG11201601203TA (en) | 2016-03-30 |
EP3146966A1 (en) | 2017-03-29 |
KR20160052582A (ko) | 2016-05-12 |
JP2016529327A (ja) | 2016-09-23 |
WO2015036370A1 (en) | 2015-03-19 |
PH12016500472A1 (en) | 2016-05-16 |
CA2922739A1 (en) | 2015-03-19 |
PE20160649A1 (es) | 2016-07-09 |
EA201690574A1 (ru) | 2016-09-30 |
AU2014320474A1 (en) | 2016-03-24 |
CN105555267A (zh) | 2016-05-04 |
IL244435A0 (en) | 2016-04-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2015003690A1 (es) | Uso de pridopidina o una sal de la misma para preparar un medicamento útil en el tratamiento de la enfermedad de huntington. | |
DK3727555T3 (da) | Oral delivery of active drug substances | |
EA201591679A1 (ru) | Способ нетоксического лечения абстиненции, вызванной лекарственным средством | |
CL2016001918A1 (es) | Heteroaril amidas como inhibidores de agregación de proteína | |
CL2015002835A1 (es) | Nuevos derivados de piridina | |
CO2017005732A2 (es) | Compuestos de dihidropirimidin-2-ona y sus usos médicos | |
CR20150266A (es) | Formulaciones de liberación modificada para oprozomib | |
ECSP16086247A (es) | (s)-pirlindole y sus sales farmacéuticamente aceptables para uso en medicina | |
CY1121566T1 (el) | Νευροπροστατευτικο και ενδειξη αυτου | |
EA201691860A1 (ru) | Пептидный медикамент в виде сухого порошка | |
EP3162804A8 (en) | New benzodiazepine derivative and use thereof | |
ECSP18060864A (es) | Derivados de 3-(carboximetil)-8-amino-2-oxo-1,3-diaza-espiro-[4.5]- decano | |
DOP2016000297A (es) | Composiciones farmacéuticas útiles para tratar enfermedades infecciosas | |
EA201501164A1 (ru) | Твердая фармацевтическая лекарственная форма | |
GB2534488A (en) | Measured dose dispenser | |
CL2016000543A1 (es) | Uso de pidotimod o sus estereoisómeros y/o sales fisiológicamente aceptables para preparar un medicamento útil en el tratamiento de enfermedades asociadas con la inflamación, donde hay una hiperactivación aberrante de la vía no canónica de nfkb. | |
ECSP16086232A (es) | (r) -pirlindole y sus sales farmacéuticamente aceptables para uso en medicina | |
DOP2015000175A (es) | Uso de un péptido natriurético, un péptido diurético o un péptido vasodilatador en la elaboración de un medicamento para tratar una condición cardiovascular | |
TR201905218T4 (tr) | Nörodejenerati̇f hastaliklarin tedavi̇si̇ i̇çi̇n yararli vi̇tanoli̇dler. | |
ECSP15033649A (es) | Un medicamento combinado que comprende fenilefrina y paracetamol | |
MX2022001772A (es) | Formulaciones de isotretinoina y usos y metodos de las mismas. | |
CL2017003465A1 (es) | Uso combinado de bumetanida con ácido valproico o una de sus sales farmacéuticamente aceptables para restablecer la homeostasis de cl- y con ello, permitir la preparación de un fármaco efectivo en el tratamiento de la epilepsia, y especialmente, en el tratamiento de la epilepsia refractaria. | |
FR3011736B1 (fr) | Seringue d'administration orale de produit | |
UA94524U (uk) | Засіб для догляду за шкірою | |
SG10201809418VA (en) | New administration routes of insulin, insulin analogs or derivatives of insulin |